My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

29.08 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 15, 2023

Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.

Via Benzinga

Dow Surges Over 300 Points; Kroger Profit Beats Views ↗

June 15, 2023

U.S. stocks traded higher midway through trading, with Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.98% to 34,313.85 while the NASDAQ rose 0.73% to 13,726.16. The S&P 500,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗

June 15, 2023

Via Benzinga

Mersana Therapeutics's Return On Capital Employed Insights ↗

May 24, 2023

Via Benzinga

US Stocks Open Higher; Retail Sales Rise In May ↗

June 15, 2023

U.S. stocks traded higher this morning, with Dow Jones gaining around 180 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 34,159.59 while the NASDAQ rose 0.18% to...

Via Benzinga

Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser ↗

June 15, 2023

Markets gave back some ground after consideration of the Fed's latest interest rate decision.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 15, 2023

Via Benzinga

Why Are Mersana Therapeutics Shares Nosediving Today ↗

June 15, 2023

The FDA has issued a partial clinical hold pausing new patient enrollment in Mersana Therapeutics Inc's (NASDAQ: MRSN) UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in

Via Benzinga

7 Stocks to Buy for 200% Returns This Year ↗

June 13, 2023

These high return stock investments all have the potential to triple in 2023 based on Wall Street expectations.

Via InvestorPlace

FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death ↗

March 13, 2023

Via Benzinga

Mersana Therapeutics's Return On Capital Employed Insights ↗

November 30, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 03, 2023

Via Benzinga

US Stocks Edge Higher; AMD Shares Tank Despite Upbeat Results ↗

May 03, 2023

U.S. stocks traded up this morning, ahead of the Federal Reserve’s decision on an interest rate hike. Following the market opening Wednesday, the Dow traded up 0.05% to 33,700.93 while the NASDAQ rose...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗

March 16, 2023

Via Benzinga

With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics ↗

January 20, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 03, 2023

Via Benzinga

Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗

December 23, 2022

Via Benzinga

Recap: Mersana Therapeutics Q3 Earnings ↗

November 07, 2022

Mersana Therapeutics (NASDAQ:MRSN) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Mersana Therapeutics...

Via Benzinga

Myovant Sciences And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

October 24, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate ↗

September 12, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or...

Via Benzinga

Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗

November 08, 2022

Gainers

Via Benzinga

Mersana Therapeutics's Return On Capital Employed Insights ↗

September 01, 2022

Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $4.28 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.5%, resulting in a loss of $52.22...

Via Benzinga

Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday ↗

October 06, 2022

Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 16, 2022

Via Benzinga

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗

August 10, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 09, 2022

Via Benzinga

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session ↗

August 09, 2022

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....

Via Benzinga

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2 ↗

August 09, 2022

U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.